{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:45:26Z","timestamp":1785746726508,"version":"3.56.0"},"reference-count":49,"publisher":"Akademiai Kiado Zrt.","issue":"31","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,8,2]]},"abstract":"<jats:p>Az albuminuria a kr\u00f3nikus vesebetegs\u00e9g egyik legfontosabb biomarkere \u00e9s egyben\n                    ter\u00e1pi\u00e1san befoly\u00e1solhat\u00f3 c\u00e9lpont. A vizelettel \u00fcr\u00fcl\u0151 albumin mennyis\u00e9ge a\n                    vesefunkci\u00f3-roml\u00e1s, a cardiovascularis esem\u00e9nyek \u00e9s az \u00f6sszmortalit\u00e1s \u00f6n\u00e1ll\u00f3\n                    prediktora. Meghat\u00e1roz\u00e1sa a legegyszer\u0171bben a reggeli els\u0151 vizeletmint\u00e1b\u00f3l\n                    meghat\u00e1rozott albumin\/kreatinin h\u00e1nyados (ACR) alapj\u00e1n t\u00f6rt\u00e9nik; az esetek\n                    t\u00falnyom\u00f3 h\u00e1nyad\u00e1ban nincs sz\u00fcks\u00e9g 24 \u00f3r\u00e1s vizeletgy\u0171jt\u00e9sre. Az albuminuria\n                    patofiziol\u00f3gi\u00e1j\u00e1nak k\u00f6z\u00e9ppontj\u00e1ban a glomerularis filtr\u00e1ci\u00f3s barrier \u2013 k\u00fcl\u00f6n\u00f6sen\n                    a podocyt\u00e1k \u2013 s\u00e9r\u00fcl\u00e9se, a hemodinamikai hiperfiltr\u00e1ci\u00f3, a tubularis\n                    feh\u00e9rjereabszorpci\u00f3hoz kapcsol\u00f3d\u00f3 gyullad\u00e1s \u00e9s a renin-angiotenzin-aldoszteron\n                    rendszer (RAAS) aktiv\u00e1ci\u00f3ja \u00e1ll. A modern n\u00e9gypill\u00e9res farmakoter\u00e1pia \u2013\n                    RAS-g\u00e1tl\u00f3 (ACE-g\u00e1tl\u00f3\/ARB), SGLT2-g\u00e1tl\u00f3, nemszteroid\n                    mineralokortikoidreceptor-antagonista (finerenon) \u00e9s 2-es t\u00edpus\u00fa diabetesben\n                    GLP1-receptor-agonista \u2013 egym\u00e1st kieg\u00e9sz\u00edt\u0151 mechanizmusokon kereszt\u00fcl hat ezekre\n                    a folyamatokra. A kezel\u00e9s az albuminuria m\u00e9rt\u00e9k\u00e9hez \u00e9s az eGFR-\u00e9rt\u00e9khez igaz\u00edtva\n                    \u00e9rdemben lass\u00edtja a kr\u00f3nikus vesebetegs\u00e9g progresszi\u00f3j\u00e1t, \u00e9s cs\u00f6kkenti a\n                    cardiovascularis rizik\u00f3t. Az albuminuria m\u00e9r\u00e9se \u00e9s monitoroz\u00e1sa ez\u00e9rt a\n                    mindennapi klinikai (egyben h\u00e1ziorvosi) gyakorlat elengedhetetlen r\u00e9sze kell,\n                    hogy legyen. Orv Hetil. 2026; 167(31): 1231\u20131237.<\/jats:p>","DOI":"10.1556\/650.2026.33622","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:51:34Z","timestamp":1785739894000},"page":"1231-1237","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Albuminuria a kr\u00f3nikus vesek\u00e1rosod\u00e1s kimutat\u00e1s\u00e1ra: biomarker \u00e9s ter\u00e1pi\u00e1s c\u00e9lpont"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0055-7346","authenticated-orcid":true,"given":"Barna","family":"V\u00e1s\u00e1rhelyi","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Laborat\u00f3riumi Medicina Int\u00e9zet Budapest, Nagyv\u00e1rad t\u00e9r 4., 1089 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Tisl\u00e9r","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Grams ME, Coresh J, Matsushita K, et al. Estimated glomerular\n                    filtration rate, albuminuria, and adverse outcomes: an individual-participant\n                    meta-analysis. JAMA 2023; 330: 1266-1277.\n                        https:\/\/doi.org\/10.1001\/jama.2023.17002","DOI":"10.1001\/jama.2023.17002"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Herrington WG, Judge PK, Grams ME, et al. Chronic kidney disease.\n                    Lancet 2026; 407: 90-104.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(25)01942-7","DOI":"10.1016\/S0140-6736(25)01942-7"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Anker SD, et al. Albuminuria and heart failure:\n                    JACC state-of-the-art review. J Am Coll Cardiol. 2023; 81: 270-282.\n                        https:\/\/doi.org\/10.1016\/j.jacc.2022.10.028","DOI":"10.1016\/j.jacc.2022.10.028"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in\n                    acute and chronic kidney disease. N Engl J Med. 2022; 386: 2120-2128.\n                        https:\/\/doi.org\/10.1056\/NEJMra2201153","DOI":"10.1056\/NEJMra2201153"},{"key":"R5","unstructured":"Diagnosis and management of chronic kidney disease in adults:\n                    Hungarian clinical practice guideline. [A Bel\u00fcgyminiszt\u00e9rium eg\u00e9szs\u00e9g\u00fcgyi\n                    szakmai ir\u00e1nyelve a feln\u0151ttkori id\u00fclt vesebetegs\u00e9g diagn\u00f3zis\u00e1r\u00f3l \u00e9s\n                    kezel\u00e9s\u00e9r\u0151l.] Hypertonia Nephrol. 2025; 29(Suppl 1): S1-S48.\n                    [Hungarian]"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 clinical\n                    practice guideline for the evaluation and management of chronic kidney disease.\n                    Kidney Int. 2024; 105(Suppl 4): S117-S314.\n                        https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for\n                    Diabetes. 11. Chronic kidney disease and risk management: Standards of care in\n                    diabetes - 2026. Diabetes Care 2026; 49(Suppl 1): S246-S260.\n                        https:\/\/doi.org\/10.2337\/dc26-S011","DOI":"10.2337\/dc26-S011"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice\n                    guideline for the management of glomerular diseases. Kidney Int. 2021; 100(Suppl\n                    4): S1-S276.\n                    https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"De Boer IH, Khunti K, Sadusky T, et al. Diabetes management in\n                    chronic kidney disease: a consensus report by the American Diabetes Association\n                    (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;\n                    102: 974-989.\n                    https:\/\/doi.org\/10.1016\/j.kint.2022.08.012","DOI":"10.1016\/j.kint.2022.08.012"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease.\n                    Lancet 2017; 389: 1238-1252.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5","DOI":"10.1016\/S0140-6736(16)32064-5"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Pasternak M, Liu P, Quinn R, et al. Association of albuminuria and\n                    regression of chronic kidney disease in adults with newly diagnosed moderate to\n                    severe chronic kidney disease. JAMA Netw Open 2022; 5: e2225821.\n                        https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25821","DOI":"10.1001\/jamanetworkopen.2022.25821"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Bjornstad P, Narongkiatikhun P, Benzing T, et al. A comprehensive\n                    framework for kidney function assessment: summary of the National Institute of\n                    Diabetes and Digestive and Kidney Diseases Reimagining Kidney Function\n                    Assessment Workshop. Kidney Int Rep. 2025; 10: 2919-2936.\n                        https:\/\/doi.org\/10.1016\/j.ekir.2025.06.040","DOI":"10.1016\/j.ekir.2025.06.040"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in\n                    children. Lancet 2018; 392: 61-74. Erratum: Lancet 2018; 392: 282.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","DOI":"10.1016\/S0140-6736(18)30536-1"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Schl\u00f6ndorff D, Wyatt CM, Campbell KN. Revisiting the determinants of\n                    the glomerular filtration barrier: what goes round must come round. Kidney Int.\n                    2017; 92: 533-536.\n                    https:\/\/doi.org\/10.1016\/j.kint.2017.06.003","DOI":"10.1016\/j.kint.2017.06.003"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Benzing T, Salant D. Insights into glomerular filtration and\n                    albuminuria. N Engl J Med. 2021; 384: 1437-1446.\n                        https:\/\/doi.org\/10.1056\/NEJMra1808786","DOI":"10.1056\/NEJMra1808786"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Jiang H, Shen Z, Zhuang J, et al. Understanding the podocyte immune\n                    responses in proteinuric kidney diseases: from pathogenesis to therapy. Front\n                    Immunol. 2024; 14: 1335936.\n                        https:\/\/doi.org\/10.3389\/fimmu.2023.1335936","DOI":"10.3389\/fimmu.2023.1335936"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Romero-Gonz\u00e1lez G, Rodr\u00edguez-Chitiva N, Ca\u00f1ameras C, et al.\n                    Albuminuria forgotten no more: underlining the emerging role in cardiorenal\n                    crosstalk. J Clin Med. 2024; 13: 777.\n                        https:\/\/doi.org\/10.3390\/jcm13030777","DOI":"10.3390\/jcm13030777"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Liu D, Wen Y, Tang TT, et al. Megalin\/cubilin-lysosome-mediated\n                    albumin reabsorption is involved in the tubular cell activation of NLRP3\n                    inflammasome and tubulointerstitial inflammation. J Biol Chem. 2015; 290:\n                    18018-18028. https:\/\/doi.org\/10.1074\/jbc.M115.662064","DOI":"10.1074\/jbc.M115.662064"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"D\u2019Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int.\n                    2003; 63: 809-825.\n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00840.x","DOI":"10.1046\/j.1523-1755.2003.00840.x"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Garsen M, Rops AL, Rabelink TJ, et al. The role of heparanase and\n                    the endothelial glycocalyx in the development of proteinuria. Nephrol Dial\n                    Transplant. 2014; 29: 49-55.\n                    https:\/\/doi.org\/10.1093\/ndt\/gft410","DOI":"10.1093\/ndt\/gft410"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies.\n                    N Engl J Med. 1998; 339: 1448-1456.\n                        https:\/\/doi.org\/10.1056\/NEJM199811123392007","DOI":"10.1056\/NEJM199811123392007"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Morales J, Handelsman Y. Cardiovascular outcomes in patients with\n                    diabetes and kidney disease. J Am Coll Cardiol. 2023; 82: 161-170.\n                        https:\/\/doi.org\/10.1016\/j.jacc.2023.04.052","DOI":"10.1016\/j.jacc.2023.04.052"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Cooper TE, Teng C, Tunnicliffe DJ, et al. Angiotensin-converting\n                    enzyme inhibitors and angiotensin receptor blockers for adults with early (stage\n                    1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023;\n                    7: CD007751.\n                    https:\/\/doi.org\/10.1002\/14651858.CD007751.pub3","DOI":"10.1002\/14651858.CD007751.pub3"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Cherney DZ, Odutayo A, Aronson R, et al. Sodium glucose\n                    cotransporter-2 inhibition and cardiorenal protection. J Am Coll Cardiol. 2019;\n                    74: 2511-2524.\n                    https:\/\/doi.org\/10.1016\/j.jacc.2019.09.022","DOI":"10.1016\/j.jacc.2019.09.022"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Thomson SC, Vallon V. Effects of SGLT2 inhibitor and dietary NaCl on\n                    glomerular hemodynamics assessed by micropuncture in diabetic rats. Am J Physiol\n                    Renal Physiol. 2021; 320: F761-F771.\n                        https:\/\/doi.org\/10.1152\/ajprenal.00552.2020","DOI":"10.1152\/ajprenal.00552.2020"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Natale P, Tunnicliffe DJ, Toyama T, et al. Sodium-glucose\n                    co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney\n                    disease (CKD) and diabetes. Cochrane Database Syst Rev. 2024; 5: CD015588.\n                        https:\/\/doi.org\/10.1002\/14651858.CD015588.pub2","DOI":"10.1002\/14651858.CD015588.pub2"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose\n                    co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney\n                    disease. J Cell Physiol. 2022; 237: 1182-1205.\n                        https:\/\/doi.org\/10.1002\/jcp.30621","DOI":"10.1002\/jcp.30621"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on\n                    chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med.\n                    2020; 383: 2219-2229.\n                    https:\/\/doi.org\/10.1056\/NEJMoa2025845","DOI":"10.1056\/NEJMoa2025845"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal\n                    mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J.\n                    2021; 42: 152-161.\n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Fioretti F, Testani JM, Tio MC, et al. Aldosterone and aldosterone\n                    modulation in cardio-kidney diseases. J Am Coll Cardiol. 2025; 86: 354-373.\n                        https:\/\/doi.org\/10.1016\/j.jacc.2025.06.012","DOI":"10.1016\/j.jacc.2025.06.012"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Iwakura T, Kidokoro K, Tatsugawa R, et al. Finerenone improves\n                    albuminuria via MR-TRPC signaling in diabetic kidney disease. Hypertension 2026;\n                    83: e25739.\n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.125.25739","DOI":"10.1161\/HYPERTENSIONAHA.125.25739"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Pandey AK, Bhatt DL, Cosentino F, et al. Non-steroidal\n                    mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J.\n                    2022; 43: 2931-2945. Erratum: Eur Heart J. 2022; 43: 4391.\n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehac299","DOI":"10.1093\/eurheartj\/ehac299"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, et al. GLP-1 receptor agonists and\n                    next-generation incretin-based medications: metabolic, cardiovascular, and renal\n                    benefits. Lancet 2026; 407: 892-908. Erratum: Lancet 2026; 407: 1058.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(25)02105-1","DOI":"10.1016\/S0140-6736(25)02105-1"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Mann JF, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal\n                    outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 839-848.\n                        https:\/\/doi.org\/10.1056\/NEJMoa1616011","DOI":"10.1056\/NEJMoa1616011"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on\n                    chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;\n                    391: 109-121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Sasaki T, Giang SM, Wu J, et al. The effect of GLP-1 receptor\n                    agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial\n                    Transplant. 2026; 41: 681-691.\n                    https:\/\/doi.org\/10.1093\/ndt\/gfaf193","DOI":"10.1093\/ndt\/gfaf193"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney\n                    outcomes by glomerular filtration rate (GFR) and albuminuria. A metaanalysis.\n                    JAMA 2026; 335: 233-244.\n                    https:\/\/doi.org\/10.1001\/jama.2025.20834","DOI":"10.1001\/jama.2025.20834"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Rossing P, Caramori M, Chan J, et al. KDIGO 2022 clinical practice\n                    guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;\n                    102(Suppl 5): S1-S127.\n                    https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Jongs N, Greene T, Chertow G, et al. Effect of dapagliflozin on\n                    urinary albumin excretion in patients with chronic kidney disease with and\n                    without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet\n                    Diabetes Endocrinol. 2021; 9: 755-766.\n                        https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6","DOI":"10.1016\/S2213-8587(21)00243-6"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Heerspink HJ, Birkenfeld AL, Cherney DZ, et al. Finerenone in type 1\n                    diabetes and chronic kidney disease. N Engl J Med. 2026; 394: 947-957.\n                        https:\/\/doi.org\/10.1056\/NEJMoa2512854","DOI":"10.1056\/NEJMoa2512854"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Wing S, Ray JG, Yau K, et al. SGLT2 inhibitors and risk for\n                    hyperkalemia among individuals receiving RAAS inhibitors. JAMA Intern Med. 2025;\n                    185: 827-836. Erratum: JAMA Intern Med. 2026; 186: 786.\n                        https:\/\/doi.org\/10.1001\/jamainternmed.2025.0686","DOI":"10.1001\/jamainternmed.2025.0686"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Agarwal R, Green JB, Heerspink HJ, et al. Risk of hyperkalemia with\n                    empagliflozin, finerenone, or both. Secondary analysis of the CONFIDENCE\n                    randomized trial. J Am Coll Cardiol. 2026; 87: 772-784.\n                        https:\/\/doi.org\/10.1016\/j.jacc.2025.10.049","DOI":"10.1016\/j.jacc.2025.10.049"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations\n                    for laboratory analysis in the diagnosis and management of diabetes mellitus.\n                    Diabetes Care 2023; 46: e151-e199.\n                    https:\/\/doi.org\/10.2337\/dci23-0036","DOI":"10.2337\/dci23-0036"},{"key":"R44","unstructured":"Goodbred AJ, Langan RC. Chronic kidney disease: prevention,\n                    diagnosis, and treatment. Am Fam Physician 2023; 108: 554-561."},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Beck LH Jr., Ayoub I, Caster D, et al. KDOQI US commentary on the\n                    2021 KDIGO clinical practice guideline for the management of glomerular\n                    diseases. Am J Kidney Dis. 2023; 82: 121-175.\n                        https:\/\/doi.org\/10.1053\/j.ajkd.2023.02.003","DOI":"10.1053\/j.ajkd.2023.02.003"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney\n                    function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.\n                        https:\/\/doi.org\/10.1001\/jama.2010.39","DOI":"10.1001\/jama.2010.39"},{"key":"R47","unstructured":"Toth-Manikowski S, Shaps H, Danziger J. Updates to management of\n                    adults with chronic kidney disease. Am Fam Physician 2025; 111:\n                    202-204."},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Staplin N, Roddick AJ, Neuen BL, et al. Effects of sodium glucose\n                    cotransporter 2 (SGLT2) inhibitors by diabetes status and level of albuminuria:\n                    a metaanal\u00edzis. JAMA 2026; 335: 220-232.\n                        https:\/\/doi.org\/10.1001\/jama.2025.20835","DOI":"10.1001\/jama.2025.20835"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Song RM, Alexander JT, Prochaska M. Delaying progression of chronic\n                    kidney disease. JAMA 2025; 334: 629-630.\n                        https:\/\/doi.org\/10.1001\/jama.2025.9532","DOI":"10.1001\/jama.2025.9532"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/31\/article-p1231.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/31\/article-p1231.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/31\/article-p1231.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:57:42Z","timestamp":1785743862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/31\/article-p1231.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":49,"journal-issue":{"issue":"31"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33622","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}